Avita Medical Research and Development Expenses 2011-2024 | RCEL

Avita Medical research and development expenses from 2011 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

Avita Medical Research and Development Expenses 2011-2024 | RCEL

Avita Medical research and development expenses from 2011 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$87.5B
Takeda Pharmaceutical (TAK)$47.5B
Merck (MKGAF)$24.4B
Astellas Pharma (ALPMY)$22B
Sandoz Group AG (SDZNY)$17.6B
Summit Therapeutics (SMMT)$16.8B
United Therapeutics (UTHR)$15.6B
Shionogi (SGIOY)$13.3B
Neurocrine Biosciences (NBIX)$12.2B
Catalent (CTLT)$10.9B
Revolution Medicines (RVMD)$7.7B
Orion OYJ (ORINY)$7.4B
Jazz Pharmaceuticals (JAZZ)$6.9B
Ionis Pharmaceuticals (IONS)$6.2B
Hikma Pharmaceuticals Plc (HKMPF)$5.7B
Madrigal Pharmaceuticals (MDGL)$5.3B
Crinetics Pharmaceuticals (CRNX)$4.3B
Corcept Therapeutics (CORT)$4.3B
Dyne Therapeutics (DYN)$3.7B
PTC Therapeutics (PTCT)$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.5B
Soleno Therapeutics (SLNO)$2B
Recursion Pharmaceuticals (RXRX)$2B
Centessa Pharmaceuticals (CNTA)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.7B
Xencor (XNCR)$1.7B
Harrow (HROW)$1.6B
Cassava Sciences (SAVA)$1.5B